Patient care navigation and health copilot AI
Outcomes4Me
Outcomes4Me combines patient cancer education and trial discovery with a life-sciences business that offers sponsored content and recruitment. Commercial influence channels are documented. Their effect on actual treatment or trial rankings remains unverified.
Checklist assessment dated October 30, 2026. Independent confirmation is incomplete. Hugo has not personally verified this service.
Agency checklist · October 30, 2026
Mixed 5 of 12 yes
Document-based draft. Independent confirmation is incomplete. Hugo has not personally verified this service.
Assessed function: Outcomes4Me patient-facing cancer navigation and clinical trial discovery app; life-sciences business and Realyze clinical-workflow trial matching not assessed as the patient function
A no can mean missing documentation or institution-dependent control; it does not by itself establish harmful behavior. These categories are not clinical safety or product-quality ratings.
- Public documents do not establish actual product behavior.
- The independent review screened rules and selected evidence; it did not replicate all twelve answers for this tool.
See all twelve answers and their evidence
| Question | Answer | Evidence / review | Source and reasoning |
|---|---|---|---|
| 1. Told it is AI | Yes | documented Not independently replicated | uses Artificial Intelligence to translate that information so you can understand itSource From the App Store description. Terms of Service and Privacy Policy do not mention AI. In-app disclosure or consent not verified. |
| 2. Operator and model maker named | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Source Outcomes4Me Inc. is named as operator. No source names an AI model or its maker. |
| 3. Patient chooses to use it | Yes | documented Not independently replicated | Outcomes4Me is a direct-to-patient, AI-driven patient empowerment platformSource Patient downloads and registers ('direct-to-patient'). Realyze (acquired May 2026) embeds AI trial matching in clinical workflows, a separate deployment. |
| 4. Patient sets the task | No | documented Not independently replicated | display sponsored content to you, including to inform you of relevant clinical trials and available treatments offered by our partnersSource Consumer health data policy section 'For Sponsored Education'. For Life Sciences page markets 'lead generation' and sponsored content inside patient interactions. Operator steers toward partner goals. |
| 5. Patient can decline or stop | Yes | documented Not independently replicated | Outcomes4Me is a direct-to-patient, AI-driven patient empowerment platformSource Self-started rule applied (cites question 3 source). Privacy: users can use the Site without providing Personal Data. |
| 6. Patient sees the AI output | Yes | documented Not independently replicated | View treatment options and trials personalized to your diagnosisSource Patient sees treatment options and trial matches in the app. |
| 7. Patient can correct or challenge | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Source Privacy lets users update Personal Data (corrects inputs). No route to correct or contest the AI-generated treatment or trial output is documented. |
| 8. Patient can get a copy | No | documented Not independently replicated | Confirm whether we are collecting, sharing, or selling your consumer health data, and to access your consumer health dataSource Request route: [email protected]. Right is 'depending on your location'. Borderline, see caveats. |
| 9. Patient can delete | Yes | documented Not independently replicated | You may also request that we terminate your account and delete your Personal Data at any time.Source Main privacy policy; unconditional wording. |
| 10. Training or sale does not override patient choice | No | documented Not independently replicated | we may share this aggregated and/or de-identified data with our affiliates, agents and business partnersSource Terms license User Content 'as aggregated and/or de-identified for any lawful purpose'. Consumer health data policy: research partners include pharmaceutical companies. Withdrawal of consent is location-dependent. No AI-training statement either way. |
| 11. Patient can run it or take it elsewhere | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Source Vendor-hosted app only. |
| 12. No advertising or data business | No | documented Not independently replicated | We also may use and share consumer health data to serve and load ads and other sponsored content on certain parts of our Services.Source Also For Life Sciences page: real-world data, sponsored content and trial recruitment sold to pharma partners. Main privacy policy says 'not in the business of selling your Personal Data'; the health-data policy and Life Sciences page document the business. Answered by the more specific binding policy. |
Initial coding: Claude Sonnet helpers, compiled by Claude Opus 5.5 (Anthropic). Selective review and corrections: GPT-6 Astra (OpenAI). Editor: Hugo Campos. Acceptance of corrections is not product verification.
Checklist rules · Independent review and limitations · Later evidence follow-up
Earlier v1.3 assessment and control finding
Historical assessment under different rules. It does not set the current checklist zone.
Agency finding, before method v1.3
Mixed, strong patient education with sponsor-funded routing caveats
Legacy editorial placement, pre-method: 62
This profile has not yet been reviewed under the published method. Its finding and any number are editorial placements made before the method existed.
- Evidence
- Documentary review. Public sources only, no hands-on testing by HugoScore.
- Review status
- AI draft. No person has settled the findings.
Earlier evidence and assessment
The sections below preserve the earlier review. Its classifications and provenance are historical; the checklist above gives the current draft classification.
Earlier finding · Legacy editorial placement, pre-method: 62
Method v1.3. The control line is evidence for how the agency finding arose, not a quality score. Legacy editorial placement, pre-method: 62. Not comparable with v1.3 positions.
Mixed, strong patient education with sponsor-funded routing caveats
Outcomes4Me combines patient cancer education and trial discovery with a life-sciences business that offers sponsored content and recruitment. Commercial influence channels are documented. Their effect on actual treatment or trial rankings remains unverified.
Patient agency
How this tool changes agency
Guideline-derived education in the baseline expands the questions a patient can ask. Sponsor labeling in one public example is useful, but does not verify in-app treatment or trial ordering.
Live sponsored labeling, ranking, diagnosis correction and retention after withdrawal remain unverified
Patient agency assessment
Who sets and changes the goal?
The historical patient workflow lets people seek treatment information and trials. The current sponsor offering establishes a competing conversion objective, but does not demonstrate patients losing their final choice.
What can the patient understand, question, or do?
Guideline-derived education in the baseline expands the questions a patient can ask. Sponsor labeling in one public example is useful, but does not verify in-app treatment or trial ordering.
Can the patient evaluate the conditions of use?
Secondary uses are expressly disclosed. The critical question is whether patients can recognize and decline commercial influence while retaining useful navigation, not simply who funds the service.
Text findings
Conditions of use
Published controls and their limits
Secondary uses are expressly disclosed. The critical question is whether patients can recognize and decline commercial influence while retaining useful navigation, not simply who funds the service.
What remains unknown?
Not tested or not established
Live sponsored labeling, ranking, diagnosis correction and retention after withdrawal remain unverified
Who evaluated this?
AI-assisted public-source draft
Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.
Sources checked
Source-specific findings and retrieval limitations are recorded in the full report.
Earlier review provenance
Criteria
CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.
Reviewer
AI-assisted public-source reassessment prepared in OpenAI Codex.
AI / model
OpenAI Codex / GPT-6
Human review
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
Review date
2026-09-08
Limitations
Live sponsored labeling, ranking, diagnosis correction and retention after withdrawal remain unverified No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.
Earlier review method
Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
Document-based draft · Moderate for disclosed purposes and commercial offering (AI-assisted draft)